Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2004 Apr;112(5):616–619. doi: 10.1289/ehp.6542

Asbestos-induced peritoneal mesothelioma in a construction worker.

Rodolfo Fonte 1, Salvatore Gambettino 1, Mario Melazzini 1, Mario Scelsi 1, Claudio Zanon 1, Stefano M Candura 1
PMCID: PMC1241930  PMID: 15064170

Abstract

Occupational and environmental asbestos exposure continues to represent a public health problem, despite increasingly restrictive laws adopted by most industrialized countries. Peritoneal mesothelioma is a rare and aggressive asbestos-related malignancy. We present the case of a 65-year-old man who developed recurrent ascites after having been exposed to asbestos in the building industry for > 40 years. Liver function and histology were normal. Abdominal computed tomography initially excluded the presence of expansive processes, and no abnormal cells were found in the ascitic fluid. Laparoscopy showed diffuse neoplastic infiltration of the peritoneum. Histopathology of bioptic samples revealed epithelioid neoplastic proliferation with a tubulopapillary pattern, falsely suggesting metastatic adenocarcinomatosis. In consideration of the occupational history, and after further diagnostic procedures had failed to identify the hypothetical primitive tumor, immunostaining of the neoplastic tissue was performed. Results were negative for carcinoembrionary antigen and the epithelial glycoprotein Ber-EP4, whereas results were positive for the mesothelial markers cytokeratins, calretinin, epithelial membrane antigen, and HBME-1, thus leading to the correct diagnosis of peritoneal epithelial mesothelioma. The Italian Workers' Compensation Authority recognized the occupational origin of the disease. Cytoreductive surgery associated with continuous hyperthermic peritoneal perfusion (cisplatin at 42 degrees C, for 1 hr) was performed. The disease relapsed after 4 months and was later complicated by a bowel obstruction requiring palliative ileostomy. The patient died 23 months after diagnosis. This case illustrates the insidious diagnostic problems posed by peritoneal mesothelioma, a tumor which often simulates other malignancies (e.g., metastatic carcinomas) at routine histopathological examination. Occupational history and immunohistochemistry are helpful for the correct diagnosis, which, in turn, is important in relation to prognosis and treatment (adoption of new integrated procedures that seem to promise prolonged survival and increased quality of life), and in relation to medicolegal issues and occupation-related compensation claims following asbestos exposure.

Full Text

The Full Text of this article is available as a PDF (575.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. H. Natural history and epidemiology of malignant mesothelioma. Chest. 1993 Apr;103(4 Suppl):373S–376S. doi: 10.1378/chest.103.4_supplement.373s. [DOI] [PubMed] [Google Scholar]
  2. Antman K. H., Pomfret E. A., Aisner J., MacIntyre J., Osteen R. T., Greenberger J. S. Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol. 1983 Jun;1(6):386–391. doi: 10.1200/JCO.1983.1.6.386. [DOI] [PubMed] [Google Scholar]
  3. Attanoos R. L., Gibbs A. R. Pathology of malignant mesothelioma. Histopathology. 1997 May;30(5):403–418. doi: 10.1046/j.1365-2559.1997.5460776.x. [DOI] [PubMed] [Google Scholar]
  4. Attanoos R. L., Webb R., Dojcinov S. D., Gibbs A. R. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology. 2001 Dec;39(6):584–588. doi: 10.1046/j.1365-2559.2001.01295.x. [DOI] [PubMed] [Google Scholar]
  5. Auerbach O., Conston A. S., Garfinkel L., Parks V. R., Kaslow H. D., Hammond E. C. Presence of asbestos bodies in organs other than the lung. Chest. 1980 Feb;77(2):133–137. doi: 10.1378/chest.77.2.133. [DOI] [PubMed] [Google Scholar]
  6. Averbach A. M., Sugarbaker P. H. Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res. 1996;81:193–211. doi: 10.1007/978-1-4613-1245-1_17. [DOI] [PubMed] [Google Scholar]
  7. Browne K., Smither W. J. Asbestos-related mesothelioma: factors discriminating between pleural and peritoneal sites. Br J Ind Med. 1983 May;40(2):145–152. doi: 10.1136/oem.40.2.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chiappino G. Il problema amianto oggi. G Ital Med Lav Ergon. 1998 Jul-Sep;20(3):200–202. [PubMed] [Google Scholar]
  9. Chiappino G., Mensi C., Riboldi L., Rivolta G. Il rischio amianto nel settore tessile: indicazioni dal Registro Mesoteliomi Lombardia e definitiva conferma. Med Lav. 2003 Nov-Dec;94(6):521–530. [PubMed] [Google Scholar]
  10. Craighead J. E., Mossman B. T. The pathogenesis of asbestos-associated diseases. N Engl J Med. 1982 Jun 17;306(24):1446–1455. doi: 10.1056/NEJM198206173062403. [DOI] [PubMed] [Google Scholar]
  11. Doglioni C., Dei Tos A. P., Laurino L., Iuzzolino P., Chiarelli C., Celio M. R., Viale G. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996 Sep;20(9):1037–1046. doi: 10.1097/00000478-199609000-00001. [DOI] [PubMed] [Google Scholar]
  12. Hourihane D. O. A biopsy series of mesotheliomata, and attempts to identify asbestos within some of the tumors. Ann N Y Acad Sci. 1965 Dec 31;132(1):647–673. doi: 10.1111/j.1749-6632.1965.tb41143.x. [DOI] [PubMed] [Google Scholar]
  13. KEAL E. E. Asbestosis and abdominal neoplasms. Lancet. 1960 Dec 3;2(7162):1211–1216. doi: 10.1016/s0140-6736(60)92413-2. [DOI] [PubMed] [Google Scholar]
  14. King J. E., Hasleton P. S. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology. 2001 May;38(5):471–476. doi: 10.1046/j.1365-2559.2001.01092.x. [DOI] [PubMed] [Google Scholar]
  15. Lanphear B. P., Buncher C. R. Latent period for malignant mesothelioma of occupational origin. J Occup Med. 1992 Jul;34(7):718–721. [PubMed] [Google Scholar]
  16. Leers M. P., Aarts M. M., Theunissen P. H. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology. 1998 Mar;32(3):209–216. doi: 10.1046/j.1365-2559.1998.00349.x. [DOI] [PubMed] [Google Scholar]
  17. Ma G. Y., Bartlett D. L., Reed E., Figg W. D., Lush R. M., Lee K. B., Libutti S. K., Alexander H. R. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am. 1997 May-Jun;3(3):174–179. [PubMed] [Google Scholar]
  18. Magnani C., Mollo F., Paoletti L., Bellis D., Bernardi P., Betta P., Botta M., Falchi M., Ivaldi C., Pavesi M. Asbestos lung burden and asbestosis after occupational and environmental exposure in an asbestos cement manufacturing area: a necropsy study. Occup Environ Med. 1998 Dec;55(12):840–846. doi: 10.1136/oem.55.12.840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Masse R., Sebastien P., Monchaux G., Bignon J. Experimental demonstration of the penetration of asbestos fibres into the gastrointestinal tract. IARC Sci Publ. 1980;(30):321–328. [PubMed] [Google Scholar]
  20. Peterson J. T., Jr, Greenberg S. D., Buffler P. A. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984 Sep 1;54(5):951–960. doi: 10.1002/1097-0142(19840901)54:5<951::aid-cncr2820540536>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  21. Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. Br J Cancer. 1999 Feb;79(3-4):666–672. doi: 10.1038/sj.bjc.6690105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rom W. N., Hammar S. P., Rusch V., Dodson R., Hoffman S. Malignant mesothelioma from neighborhood exposure to anthophyllite asbestos. Am J Ind Med. 2001 Aug;40(2):211–214. doi: 10.1002/ajim.1089. [DOI] [PubMed] [Google Scholar]
  23. Sebbag G., Yan H., Shmookler B. M., Chang D., Sugarbaker P. H. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000 Nov;87(11):1587–1593. doi: 10.1046/j.1365-2168.2000.01571.x. [DOI] [PubMed] [Google Scholar]
  24. Sridhar K. S., Doria R., Raub W. A., Jr, Thurer R. J., Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer. 1992 Dec 15;70(12):2969–2979. doi: 10.1002/1097-0142(19921215)70:12<2969::aid-cncr2820701239>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  25. Sugarbaker Paul H., Acherman Yair I. Z., Gonzalez-Moreno Santiago, Ortega-Perez Gloria, Stuart O. Anthony, Marchettini Pierre, Yoo Dal. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol. 2002 Feb;29(1):51–61. doi: 10.1053/sonc.2002.30236. [DOI] [PubMed] [Google Scholar]
  26. Vogelzang Nicholas J. Emerging insights into the biology and therapy of malignant mesothelioma. Semin Oncol. 2002 Dec;29(6 Suppl 18):35–42. doi: 10.1053/sonc.2002.37469. [DOI] [PubMed] [Google Scholar]
  27. WAGNER J. C., SLEGGS C. A., MARCHAND P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960 Oct;17:260–271. doi: 10.1136/oem.17.4.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Walker C., Everitt J., Barrett J. C. Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med. 1992;21(2):253–273. doi: 10.1002/ajim.4700210214. [DOI] [PubMed] [Google Scholar]
  29. de Bree E., Christodoulakis M., Tsiftsis D. Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy. Ann Oncol. 2000 Jun;11(6):753–756. doi: 10.1023/a:1008328120555. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES